CClinicalTrials.gg
Not yet recruitingNCT07847086Updated Sep 29, 2026

Gait Pattern and Its Relation to Cognition and VEP in Multiple Sclerosis

An observational study in Multiple Sclerosis and Gait Disorders, Neurologic, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
70
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This cross-sectional study aims to assess the pattern of gait in patients with multiple sclerosis and to evaluate its relation to cognitive function, visual evoked potentials, and radiological findings.

Read the detailed description

Gait impairment is a common and disabling feature of multiple sclerosis. This observational study will include patients with confirmed multiple sclerosis according to the revised McDonald criteria who are clinically stable.

Participants will undergo quantitative gait analysis, cognitive assessment, visual evoked potential testing, and review of MRI findings in a single assessment visit.

02

Conditions studied

  • Multiple Sclerosis
  • Gait Disorders, Neurologic

Keywords

  • Visual evoked potentials
  • Multiple sclerosis
  • Gait analysis
  • Cognition
  • Assiut
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with multiple sclerosis attending the Neurology Department outpatient clinic and gait laboratory at Assiut University.

Inclusion criteria

  • - Age 18 to 55 years
  • Confirmed diagnosis of multiple sclerosis according to the revised McDonald criteria
  • Clinically stable (no relapse or steroid treatment within 4 weeks)
  • Able to walk independently with or without a single assistive device
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • - Other neurological, orthopedic, visual, or vestibular conditions affecting gait
  • Severe cognitive impairment precluding valid testing
  • Pregnancy
  • MRI contraindications
  • Ocular disease unrelated to multiple sclerosis
04

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Multiple Sclerosis Patients

    Patients with confirmed multiple sclerosis who will undergo gait analysis, cognitive testing, visual evoked potential assessment, and MRI review in a single visit.

05

What researchers measure

Primary outcomes

  1. Mean gait velocity

    Mean gait velocity in meters per second measured by quantitative spatiotemporal gait analysis.

    Time frame: Baseline

Secondary outcomes

  1. Mean cadence

    Mean cadence in steps per minute measured by quantitative gait analysis.

    Time frame: Baseline

  2. Mean stride length

    Mean stride length in centimeters measured by quantitative gait analysis.

    Time frame: Baseline

  3. Mean MoCA score

    Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition).

    Time frame: Baseline

  4. Mean P100 latency

    Mean P100 latency in milliseconds measured by pattern-reversal visual evoked potentials.

    Time frame: Baseline

  5. Mean EDSS score

    Mean Expanded Disability Status Scale (EDSS) score.

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07847086
Lead sponsor
Assiut University
Responsible party
Manar Moataz Abdel-ghani (Resident Physician, Department of Neuropsychiatry, Assiut University) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Manar A Ali, Resident
Contact
manarmoataz2000@gmail.com
01091423914
Tarek A Rageh, prof
study chair · Neuropsychiatry Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion